Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Jean-François Guichou"'
Autor:
Alexandre Bancet, Rita Frem, Florian Jeanneret, Angélique Mularoni, Pauline Bazelle, Caroline Roelants, Jean-Guy Delcros, Jean-François Guichou, Catherine Pillet, Isabelle Coste, Toufic Renno, Christophe Battail, Claude Cochet, Thierry Lomberget, Odile Filhol, Isabelle Krimm
Publikováno v:
iScience, Vol 27, Iss 2, Pp 108903- (2024)
Summary: Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further exploring its therapeut
Externí odkaz:
https://doaj.org/article/41eefb09154c47d1a837761d86fb8080
Autor:
Amel Kheyar, Nazim Ahnou, Abdelhakim Ahmed-Belkacem, Anne Hulin, Claire Pressiat, Bijan Ghaleh, Jean-François Guichou, Didier Morin, Jean-Michel Pawlotsky, Fatima Teixeira-Clerc
Publikováno v:
JHEP Reports, Vol 5, Iss 11, Pp 100876- (2023)
Background & Aims: Mitochondrial permeability transition pore (mPTP) opening is critical for mediating cell death during hepatic ischaemia–reperfusion injury (IRI). Blocking mPTP opening by inhibiting cyclophilin D (CypD) is a promising pharmacolog
Externí odkaz:
https://doaj.org/article/e0e87a14584446d3b9a36e9525600753
Autor:
Rebecca L. Gorry, Kieran Brennan, Paul T. M. Lavin, Tayler Mazurski, Charline Mary, David Matallanas, Jean-François Guichou, Margaret M. Mc Gee
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 11084 (2023)
The isomerase activity of Cyclophilin A is important for midbody abscission during cell division, however, to date, midbody substrates remain unknown. In this study, we report that the GTP-binding protein Septin 2 interacts with Cyclophilin A. We hig
Externí odkaz:
https://doaj.org/article/bb4921fd97fd422d9d759b0b1597f4b4
Autor:
Jens Van Bael, Aline Vandenbulcke, Abdelhakim Ahmed-Belkacem, Jean-François Guichou, Jean-Michel Pawlotsky, Jelle Samyn, Arjan D. Barendrecht, Coen Maas, Simon F. De Meyer, Karen Vanhoorelbeke, Claudia Tersteeg
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 8, p 7163 (2023)
Procoagulant platelets are associated with an increased risk for thrombosis. Procoagulant platelet formation is mediated via Cyclophilin D (CypD) mediated opening of the mitochondrial permeability transition pore. Inhibiting CypD activity could there
Externí odkaz:
https://doaj.org/article/9dacc18342144244b68ab4ef4aa16ab8
Autor:
Xavier Lahaye, Takeshi Satoh, Matteo Gentili, Silvia Cerboni, Aymeric Silvin, Cécile Conrad, Abdelhakim Ahmed-Belkacem, Elisa C. Rodriguez, Jean-François Guichou, Nathalie Bosquet, Matthieu Piel, Roger Le Grand, Megan C. King, Jean-Michel Pawlotsky, Nicolas Manel
Publikováno v:
Cell Reports, Vol 15, Iss 4, Pp 879-892 (2016)
During the early phase of replication, HIV reverse transcribes its RNA and crosses the nuclear envelope while escaping host antiviral defenses. The host factor Cyclophilin A (CypA) is essential for these steps and binds the HIV capsid; however, the m
Externí odkaz:
https://doaj.org/article/fe92c4c74c7046739a91e7a5b56b2a1a
Autor:
Floriane Gibault, Mathilde Coevoet, Manon Sturbaut, Amaury Farce, Nicolas Renault, Frédéric Allemand, Jean-François Guichou, Anne-Sophie Drucbert, Catherine Foulon, Romain Magnez, Xavier Thuru, Matthieu Corvaisier, Guillemette Huet, Philippe Chavatte, Patricia Melnyk, Fabrice Bailly, Philippe Cotelle
Publikováno v:
Cancers, Vol 10, Iss 5, p 140 (2018)
Intrinsically disordered protein YAP (yes-associated protein) interacts with TEADs transcriptional factors family (transcriptional enhancer associated domain) creating three interfaces. Interface 3, between the Ω-loop of YAP and a shallow pocket of
Externí odkaz:
https://doaj.org/article/577e777214884ea1a55d9d4629a58796
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e102300 (2014)
Fragment-based drug design is one of the most promising approaches for discovering novel and potent inhibitors against therapeutic targets. The first step of the process consists of identifying fragments that bind the protein target. The determinatio
Externí odkaz:
https://doaj.org/article/ac6e427c7187469a8cf78c8d421844f7
Autor:
Malvina Schatz, Laetitia Marty, Camille Ounadjela, Phuoc Bao Viet Tong, Ilaria Cardace, Clément Mettling, Pierre-Emmanuel Milhiet, Luca Costa, Cédric Godefroy, Martine Pugnière, Jean-François Guichou, Jean-Michel Mesnard, Mickaël Blaise, Bruno Beaumelle
Publikováno v:
Journal of Virology. 97
SummaryHIV-1 Tat is a key viral protein that stimulates several steps of viral gene expression. Tat is especially required for the transcription of viral genes but it is still not clear if and how Tat is incorporated into HIV-1 virions. Cyclophilin A
Autor:
David Planchard, Pierre Saintigny, Jean-Yves Blay, Benjamin Besse, Maurice Perol, Jean-François Guichou, Sylvie Chabaud, Luc Friboulet, Emma Green, Clive Morris, Karen Howarth, Frank de Kievit, Natalie Hoog-Labouret, Celine Mahier-Aït Oukhatar, Caroline Caramella, Etienne Giroux Leprieur, Isabelle Monnet, Etienne Brain, Radj Gervais, Christine Raynaud, Claire Tissot, Maud Ngo-Camus, Virginie Westeel, Yohann Loriot, Ludovic Lacroix, Washington R. Chumbi Flores, Virginie Avrillon, Anne Pradines, Cecile Jovelet, Camille Leonce, Julien Mazieres, Mihalea Aldea, Aurélie Swalduz, Laura Mezquita, Sandra Ortiz-Cuaran
Purpose:The limited knowledge on the molecular profile of patients with BRAF-mutant non–small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic strategies for these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ac9163cfbba9d2de50090974b699f2
https://doi.org/10.1158/1078-0432.c.6530096
https://doi.org/10.1158/1078-0432.c.6530096
Autor:
Alexandre Bancet, Rita Frem, Florian Jeanneret, Angélique Mularoni, Pauline Bazelle, Caroline Roelants, Jean-Guy Delcros, Jean-François Guichou, Catherine Pillet, Isabelle Coste, Toufic Renno, Christophe Battail, Claude Cochet, Thierry Lomberget, Odile Filhol, Isabelle Krimm
Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further explore its therapeutic potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecc80309dd80d08e01af158a30d3d7bc
https://doi.org/10.1101/2022.12.16.520736
https://doi.org/10.1101/2022.12.16.520736